Jarrett Jennifer

RCUS COO Jarrett Jennifer sold 50,291 shares at $18.97 on 2025-11-07; stock has risen 20.2% in 30 days and 101.8% in 90 days from sale date.

Jennifer's sale of 50,291 shares at $18.97 reduced her holdings by 19.0% from 264,523 to 214,232 shares, representing a $954,065.53 transaction. The timing is notable: across her prior 5 open-market sells (cross-ticker), a 90-day well-timed rate of 100.00% indicates her previous sales have historically occurred before subsequent declines; however, at RCUS specifically, 3 of 3 measurable prior sales at this ticker also achieved negative 90-day returns (-6.1%, -9.3%, -21.4%), following the same pattern. Yet this current sale executed at $18.97 is now underwater relative to the current price of $20.00, and the stock has posted a 30-day return of +20.2% and 90-day return of +101.8% from the transaction date, contrasting with her established historical pattern. Arcus Biosciences remains unprofitable (net income $-135,000,000.00 on quarterly revenue of $26,000,000.00) despite strong annual revenue growth of +120.5%, creating fundamental volatility that may explain the sharp post-sale appreciation.

COO Jarrett Jennifer sold 50,292 shares at $14.92 blended average for $750,412.12 at RCUS, reducing holdings 19.0%.

Jarrett Jennifer, Chief Operating Officer at Arcus Biosciences, executed 2 separate sales totaling 50,292 shares for $750,412.12 on 2025-10-06 and 2025-10-08, reducing her post-transaction holdings to 214,232 shares from 264,524 shares. The blended average sale price of $14.92 occurred as the stock trades near its current level of $15.05, up 31.6% over the past 30 days and 57.8% over the past 90 days—a strong recent rally. Her prior 3 sales at RCUS were all well-timed at the 90-day mark (negative average 90-day return of -19.8%, -19.7%, and -21.4%), establishing a consistent pattern of selling before subsequent declines at this specific ticker. Her cross-ticker track record shows a 100.00% well-timed rate across 3 prior sells, though those exhibited notably weaker performance (avg 90d return -20.3% vs peers). The company itself is unprofitable with full-year net income negative, though revenues grew 120.5% year-over-year to $160,000,000, presenting a typical high-growth biotech risk profile. The materiality of this 19.0% reduction in holdings, combined with the insider's demonstrated track record of well-timed sales specifically at RCUS and the current elevated stock momentum, warrants investor attention to the underlying fundamentals.